Brief: Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
05/12/2023 13:23
Dec 5 (Reuters) - Aquestive Therapeutics Inc AQST.O :
* AQUESTIVE THERAPEUTICS DOSES FIRST PATIENT IN PHASE 3
PIVOTAL
CLINICAL STUDY EVALUATING PHARMACOKINETICS AND PHARMACODYNAMICS
OF ANAPHYLM™ (EPINEPHRINE) SUBLINGUAL FILM
* AQUESTIVE THERAPEUTICS INC - REAFFIRMS TOPLINE DATA
ANTICIPATED
IN Q1 2024
* AQUESTIVE THERAPEUTICS INC - COMMENCES INITIAL PHASE 3
STUDY
WITH FIRST ORALLY DELIVERED EPINEPHRINE PRODRUG CANDIDATE
Source text for Eikon: ID:nGNX3dhlkc
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Announces FDA Acceptance Of Anaphylm™ NDA Resubmission And PDUFA Goal Date Of March 16, 2027
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Aquestive rises on US licensing deal for seizure drug with Eton Pharma